[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-453628-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-453628-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","characteristics-and-posttransplant-outcomes-of-patients-with-congenital-and-acquired-von-willebrand-disease-and-hemophilia-a-and-with-renal-transplants","Characteristics and posttransplant outcomes of patients with congenital and acquired von Willebrand disease and hemophilia A and with renal transplants","","Bleeding disorders such as hemophilia and von Willebrand disease (VWD) are linked to morbidity, yet evidence on renal transplantation outcomes in this population is limited. A retrospective Mayo Clinic chart review assessed clinical characteristics and adverse events in renal transplant recipients with bleeding diathesis. Outcomes included post-transplant bleeding, thrombotic events, mortality, readmissions, OR takebacks, and transplant rejection. Results evaluated 11 patients with perioperative bleeding, late thrombosis risk, and notable rejection rates.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/characteristics-and-posttransplant-outcomes-of-patients-with-congenital-and-acquired-von-willebrand-disease-and-hemophilia-a-and-with-renal-transplants/453628/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/characteristics-and-posttransplant-outcomes-of-patients-with-congenital-and-acquired-von-willebrand-disease-and-hemophilia-a-and-with-renal-transplants/453628.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What endpoints were used to evaluate renal transplant recipients with bleeding diathesis?","Question",{"text":63,"@type":64},"Primary endpoints included post-transplant bleeding, thrombotic events, and mortality. Secondary endpoints included readmissions, OR takebacks, and renal transplant rejections, including acute cellular and antibody-mediated rejection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the main bleeding outcomes after renal transplantation?",{"text":68,"@type":64},"In the immediate postoperative period (days 0–30), 5 of 11 patients (45.5%) had bleeding events, including 4 major and 1 minor. No bleeding occurred between days 30 and 365, while after 1 year nonallograft-related bleeding occurred in 4 patients (36.4%), mainly gastrointestinal.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about thrombosis and rejection rates?",{"text":72,"@type":64},"No arterial or venous thrombosis occurred within 1 year, but beyond 1 year 5 thrombotic events occurred in 4 patients (36.4%). Rejection occurred in 3 patients (27.3%), including acute and chronic cellular rejection and antibody-mediated rejection.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},453628,1790765949,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","[https://doi.org/10.1016/j.rpth.2025.103279](https://doi.org/10.1016/j.rpth.2025.103279)  \nO R IG I NA L A RT IC L E  \nCharacteristics and posttransplant outcomes of patients with congenital and acquired von Willebrand disease and hemophilia A and with renal transplants  \nIsabela Wen-Chi Chang1  | Mia Truman2 | Claire Yee2 | Leslie Padrnos3  \n1Mayo Clinic Department of Internal  \nMedicine, Scottsdale, Arizona, USA 2Mayo Clinic Department of Quantitative Health Sciences, Scottsdale, Arizona, USA 3Mayo Clinic Department of Hematology and Oncology, Scottsdale, Arizona, USA  \nCorrespondence  \nIsabela Wen-Chi Chang, Mayo Clinic Department of Internal Medicine, 13400 E. Shea Blvd, Scottsdale, AZ 85259, USA. Email: [chang.isabela@mayo.edu](chang.isabela@mayo.edu)  \nHandling Editor: Dr Johnny Mahlangu  \nAbstract  \nBackground: Bleeding disorders such as hemophilia and von Willebrand disease (VWD) have historically been associated with significant morbidity due to hemarthrosis, surgical bleeding, and transfusion requirements. With advances in hemostatic therapy, surgical outcomes have improved; however, data on renal transplantation in this population remain limited.  \nObjectives: To assess clinical characteristics and adverse events in renal transplant patients with bleeding diathesis, focusing on primary endpoints: post-transplant bleeding, thrombotic events, and mortality. Secondary endpoints include readmissions, OR takebacks, and renal transplant rejections, including acute cellular rejection and antibody-mediated rejection.  \nMethods: A retrospective chart review of renal transplant patients with bleeding diathesis across Mayo Clinic.  \nResults: The cohort included 11 patients: hemophilia A (3/11) and VWD (8/11), with a mean Kidney Donor Profile Index of 37. Among patients with hemophilia A, 2 had congenital disease, and 1 had previously developed a factor VIII inhibitor that had resolved prior to transplantation. Among VWD patients, 6 had acquired VWD and 2 had type 1 VWD. No patients experienced arterial or venous thrombosis within 1 year. Beyond 1 year, 5 thrombotic events occurred in 4 patients (36.4%): 2 myocardial infarctions, 1 ischemic stroke, and 2 deep vein thromboses; no pulmonary emboli occurred. In the immediate postoperative period (days 0-30), 5 patients (45.5%) had bleeding events—4 major (80%) and 1 minor (20%). No bleeding occurred between days 30 and 365. After 1 year, 4 patients (36.4%) had nonallograft-related bleeding, primarily gastrointestinal. Readmission rates were 36.4%(0-30 days), 27.3%(30-90 days), and 9. 1%(90-365 days). Surgical reintervention was required in 18.2% of patients. Rejection occurred in 3 patients (27.3%): 2 with acute cellular rejection, 1 with chronic cellular rejection, and 1 with antibody-mediated rejection. Overall mortality was 45%. Conclusion: Kidney transplant recipients with hemophilia and VWD are at significant perioperative bleeding risk, particularly from perinephric hematomas and intraoperative hemorrhage. The risk decreases after 30 days, but long-term monitoring for  \nPublished by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the CC BY license ([http://](http://)[ ](http://)[creativecommons.org/licenses/by/4.0/](creativecommons.org/licenses/by/4.0/)).  \nRes Pract Thromb Haemost. 2026;10:e103279 [www.rpthjournal.org](www.rpthjournal.org- 1 of 9)[-](www.rpthjournal.org- 1 of 9)[ 1 of 9](www.rpthjournal.org- 1 of 9)  \n[https://doi.org/10.1016/j.rpth.2025.103279](https://doi.org/10.1016/j.rpth.2025.103279)  \n2 of 9  \n■  \nCHANG  \nET AL.  \nboth bleeding and thrombosis remains crucial. Rejection rates appear comparable with those of the general transplant population.  \nK EYW O R DS  \nbleeding diathesis, factor VIII inhibitor, hemophilia A, renal transplantation, von Willebrand disease (VWD)  \nEssentials  \n• Bleeding disorders make surgery and kidney transplant care more complex and higher risk.  \n• This study ","cbCaictg402OewhD","https://ap.wps.com/l/cbCaictg402OewhD","pdf",500797,"English","# Abstract\n## Background\n## Objectives\n## Methods\n## Results\n## Conclusion\n# Essentials\n# Introduction","[{\"question\":\"What endpoints were used to evaluate renal transplant recipients with bleeding diathesis?\",\"answer\":\"Primary endpoints included post-transplant bleeding, thrombotic events, and mortality. Secondary endpoints included readmissions, OR takebacks, and renal transplant rejections, including acute cellular and antibody-mediated rejection.\"},{\"question\":\"What were the main bleeding outcomes after renal transplantation?\",\"answer\":\"In the immediate postoperative period (days 0–30), 5 of 11 patients (45.5%) had bleeding events, including 4 major and 1 minor. No bleeding occurred between days 30 and 365, while after 1 year nonallograft-related bleeding occurred in 4 patients (36.4%), mainly gastrointestinal.\"},{\"question\":\"What did the study find about thrombosis and rejection rates?\",\"answer\":\"No arterial or venous thrombosis occurred within 1 year, but beyond 1 year 5 thrombotic events occurred in 4 patients (36.4%). Rejection occurred in 3 patients (27.3%), including acute and chronic cellular rejection and antibody-mediated rejection.\"}]","Characteristics and posttransplant outcomes of patients with congenital and acquired von Willebrand disease and hemophilia A and with renal transplants | PDF",1790739248,23]